Edition:
India

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.11USD
17 Nov 2017
Change (% chg)

$0.20 (+4.07%)
Prev Close
$4.91
Open
$5.05
Day's High
$5.12
Day's Low
$5.05
Volume
4,770
Avg. Vol
8,154
52-wk High
$12.50
52-wk Low
$4.40

Latest Key Developments (Source: Significant Developments)

Mesoblast says ‍qtrly loss attributable $7 mln
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Mesoblast Ltd ::‍Qtrly loss attributable $7 million versus loss of $19.8 million.Qtrly revenue $1.2 million versus $395,000‍​.  Full Article

MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Mesoblast Ltd ::MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS.‍INFUSIONS WERE WELL-TOLERATED AND THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED DURING 52-WEEK PERIOD IN TRIAL​.  Full Article

Mesoblast appoints Bill Burns as vice chairman
Thursday, 1 Sep 2016 

Mesoblast Ltd :Mesoblast appoints Bill Burns as vice chairman Full Article

Mesoblast reports Q4 earnings per share $0.1278
Thursday, 25 Aug 2016 

Mesoblast Ltd : Mesoblast reports financial results and operational highlights for the three months and for the year ended 30 june 2016 .Q4 earnings per share $0.1278.  Full Article

Mesoblast provides update on global heart failure program
Tuesday, 14 Jun 2016 

: Mesoblast provides update on global heart failure program . Mesoblast says regains worldwide rights to cardiovascular field for its cell therapy platform; no financial consideration to teva pharmaceuticals . Aims to complete phase 3 heart failure trial within eighteen months . To meet program's remaining funding requirements, has been offered an equity finance facility . U.S. FDA approved use of second navigational catheter system in phase 3 program for advanced heart failure . Independent committee recommends continuation of heart failure trial without modification after data review of first 175 patients . Second trial of mpc-150-im almost 60% recruited; results are expected in second half of 2017 .Has unencumbered rights to partner with a cardiovascular co with commitment to heart failure product commercialization.  Full Article

Mesoblast says co received $6.2 mln from Australian government for R&D
Friday, 20 May 2016 

Mesoblast Ltd : Mesoblast receives $6.2 million from Australian government for research and development activities . Anticipates that it will continue to receive Australian government funds for ongoing research and development activities undertaken during FY 2016 .  Full Article

BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS

* MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS